Skip to main content
SpringerLink
Log in

Secondary Prevention of Coronary Artery Disease and the Choice of the ACE Inhibitor Why EUROPA and not PEACE

  • Editorial
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. The Heart Outcomes Prevention Evaluation Study Investigators. Effect of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145–53

    Article  Google Scholar 

  2. Gomma AH, Fox KM, on behalf of the EUROPA Investigators. The EUROPA trial: design, baseline demography and status of the substudies. Cardiovasc Drugs Ther 2001;15:169–79

    Article  PubMed  CAS  Google Scholar 

  3. The European Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled multicentre trial (EUROPA). Lancet 2003;362:782–8.

    Article  CAS  Google Scholar 

  4. Deckers JW, Goedhart DM, Boersma E, et al. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur Heart J 2006;27:796–801

    Article  PubMed  CAS  Google Scholar 

  5. Remme WJ. Prevention of cardiovascular events by perindopril in patients with stable coronary disease does not depend on blood pressure and its reduction—results from the EUROPA study. Circulation 2004;110:III628 (abstract)

    Google Scholar 

  6. Bots ML, Remme WJ, Lüscher TF, et al. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc Drugs Ther 2007;21:269–79

    Article  PubMed  CAS  Google Scholar 

  7. Matsumoto T, Minai K, Horie H, Ohira N, Takashima H, Tarutani Y, et al. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol 2003;41:1373–9

    Article  PubMed  CAS  Google Scholar 

  8. Matsumoto K, Morishita R, Moriguchi A, Tomita N, Aoki M, Sakonjo H, et al. Inhibition of neointima by angiotensin-converting enzyme inhibitor in porcine coronary artery balloon-injury model. Hypertension 2001;37:270–4

    PubMed  CAS  Google Scholar 

  9. Antoni I, Lerebours G, Nitenberg A. Angiotensin converting enzyme inhibition restores flow-dependent and cold-pressure test-induced dilations in coronary arteries of hypertensive patients. Circulation 1996;94:3115–22

    Google Scholar 

  10. Candido R, Jandeleit-Dahm KA, Cao Z, Nesteroff SP, Burns WC, Twigg SM, et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002;106:246–53

    Article  PubMed  CAS  Google Scholar 

  11. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997;95:1115–8

    PubMed  CAS  Google Scholar 

  12. Fennessy PA, Campbell JH, Mendelsohn FA, Campbell GR. Angiotensin-converting enzyme inhibitors and atherosclerosis: relevance of animal models to human disease. Clin Exp Pharmacol Physiol 1996;23:530–2

    Article  Google Scholar 

  13. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003;41:1281–6

    Article  PubMed  CAS  Google Scholar 

  14. Thybo NK, Korsgaard N, Eriksen S, et al. Dose-dependent effects of perindopril on blood pressure and small-artery structure. Hypertension 1994;23:659–66

    PubMed  CAS  Google Scholar 

  15. Braunwald E, Domanski MJ, Fowler SE, et al. on behalf of the PEACE Trial Investigators. Angiotensin-converting enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058–68

    Article  PubMed  CAS  Google Scholar 

  16. Ferrari R. ACE inhibition for secondary prevention of cardiovascular events—should we change our recommendation after PEACE? Cardiovasc Drugs Ther 2006;20:11–2

    Article  PubMed  Google Scholar 

  17. Voors AA, van Veldhuisen DJ, van Gilst WH. The current role of ACE inhibitors for secondary prevention in cardiovascular disease; from pathogenesis to clinical practice. Cardiovasc Drugs Ther 2006;20:69–73

    Article  PubMed  Google Scholar 

  18. Bertrand ME, Remme WJ, Fox KM, Ferrari R, Simoons ML. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function. Int J Cardiol 2007;121:57–61

    Article  PubMed  Google Scholar 

  19. Ceconi C, Francolini G, Bastianon D, Gitti GL, Comini L, Ferrari R. Effects of angiotensin-converting enzyme (ACE) inhibition on rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther 2007;21 DOI 10.1007/s10557-007-6068-5

  20. Dzau VJ, Bernstein K, Celermajer D, et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 2002;16:149–60

    Article  PubMed  CAS  Google Scholar 

  21. Zhuo JL, Mendelsohn FAO, Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT1 receptor and nitric oxide synthase expression in patients with coronary artery disease. Hypertension 2002;39:634–8

    Article  PubMed  CAS  Google Scholar 

  22. Oosterga M, Voors AA, Buikema H, et al. on behalf of the QUO VADIS Investigators. Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. Cardiovasc Drugs Ther 2000;14:55–60

    Article  PubMed  CAS  Google Scholar 

  23. Ceconi C, Francolini G, Olivares A, Comini L, Bachetti T, Ferrari R. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol 2007 (in press)

  24. Su JB, Barbe F, Crozatier B, Campbell DJ, Hittinger L. Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure. J Cardiovasc Pharmacol 1999;34:700–10

    Article  PubMed  CAS  Google Scholar 

  25. Kim YM, Talanian RV, Billiar TR. Nitric oxide suppression of apoptosis occurs in association with an inhibition of Bcl-2 cleavage and cytochrome c release. J Biol Chem 1998;273:31437–41

    Article  PubMed  CAS  Google Scholar 

  26. Li J, Bombeck CA, Yang S, Kim YM, Billiar TR. Nitric oxide suppresses apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J Biol Chem 1997;274:17325–33

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sticares Foundation, P.O. Box 882, 3160 AB, Rotterdam, The Netherlands

    Willem J. Remme

Authors
  1. Willem J. Remme
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Willem J. Remme.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Remme, W.J. Secondary Prevention of Coronary Artery Disease and the Choice of the ACE Inhibitor Why EUROPA and not PEACE. Cardiovasc Drugs Ther 21, 405–407 (2007). https://doi.org/10.1007/s10557-007-6071-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-007-6071-x

Key words

Search

Navigation